Development of cancer therapy using suppressor of cytokine signaling (SOCS) molecules.
| Project/Area Number |
20890302
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (Start-up)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | National Institute of Biomedical Innovation |
|---|
Principal Investigator |
SERAD Satoshi National Institute of Biomedical Innovation, 基盤的研究部・免疫シグナルプロジェクト, 研究員 (50463302)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥3,302,000 (Direct Cost: ¥2,540,000、Indirect Cost: ¥762,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,742,000 (Direct Cost: ¥1,340,000、Indirect Cost: ¥402,000)
|
|---|
| Keywords | サイトカイン / SOCS / 癌 |
|---|
| Research Abstract |
Dysregulated cytokine signaling is associated with development and progression of cancers such as prostate cancer and breast cancer. In this study, we established a prostate cancer targeted therapy using suppressor of cytokine signaling (SOCS), a family of negative regulators of cytokine signaling, previously cloned in our laboratory. We demonstrated that SOCS3 showed growth inhibition activity in prostate cancer cell lines (DU145, LNCaP) in vitro. We also established a prostate cancer-specific drug delivery system using a monoclonal antibody against PSMA, a prostate cancer-specific antigen conjugated nanoparticle in vivo.
|
Report
(3 results)
Research Products
(25 results)
